Brian Dwayne Lefler, PA-C Physician Assistant - Medical Medicare: Medicare Enrolled Practice Location: 210 N Sandhill Blvd, Mesquite, NV 89027 Phone: 702-849-0558 Fax: 702-346-2147 |
Todd Michael Cravens, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 330 Falcon Ridge Pkwy Ste 400a, Mesquite, NV 89027 Phone: 435-628-9393 Fax: 435-628-9382 |
Mr. Rodney Briggs, PA-C Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 350 Falcon Ridge Parkway, Ste 500, Mesquite, NV 89027 Phone: 725-333-9026 Fax: 725-333-9027 |
News Archive
BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for female sexual health, including LibiGelĀ® for the treatment of hypoactive sexual desire disorder (HSDD), applauds the efforts of Boehringer Ingelheim to develop a therapy to treat this unmet medical need.
Breastfeeding may protect children against gluten intolerance otherwise known as coeliac disease, suggests research published ahead of print in the Archives of Disease in Childhood.
New research being presented at the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in association with the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will feature an inhalable dry powder antibiotic that when used alone or with current treatments may significantly reduce treatment for tuberculosis (TB) and multi-drug resistant TB.
An international team led by the Johns Hopkins University Applied Physics Laboratory in Laurel, Md., has developed a prototype of the first fully integrated prosthetic arm that can be controlled naturally and provide sensory feedback, and allows for eight degrees of Freedom - a level of control far beyond the current state of the art for prosthetic limbs.
Presidio Pharmaceuticals, Inc. announced today that they have selected a second clinical candidate, PPI-1301, from their hepatitis C virus (HCV) NS5A program for advancement into clinical development. Presidio's first NS5A inhibitor, PPI-461, is currently undergoing evaluation in a Phase 1a clinical study.
› Verified 7 days ago